Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatric NPs Can Do in Texas

You’re seeing it everywhere: patients asking about Ozempic, Wegovy, Mounjaro. Maybe you’ve wondered if prescribing GLP-1s for weight loss fits into your practice as a psychiatrist or PMHNP. The short answer? Yes—with the right training, state compliance, and a clear understanding of what you’re getting into.

This isn’t about chasing a trend. It’s about recognizing that metabolic and mental health are inseparable. Many of your patients struggle with medication-induced weight gain, obesity that worsens depression, or emotional eating that no amount of therapy alone will fix. Weight management is becoming part of comprehensive psychiatric care—and the reimbursement landscape is finally catching up.

But before you write your first semaglutide prescription, you need to know: What does your state allow? What does insurance cover? And is this actually within your scope?

Let’s break it down.

The Psychiatric Case for Prescribing Weight-Loss Medications

Why Psychiatrists Are Entering the Weight Management Space

Traditionally, psychiatrists prescribe psychotropics. Weight management? That’s for endocrinology or primary care, right?

Not anymore.

Here’s the reality: Your patients already have metabolic issues on your radar. You monitor glucose and lipids for patients on antipsychotics. You counsel on weight gain from SSRIs or mood stabilizers. You’ve seen how obesity exacerbates depression, ADHD, and anxiety.

GLP-1 receptor agonists (like semaglutide and tirzepatide) don’t just help people lose weight—they’re showing promise for reducing cravings, improving mood, and addressing binge eating. Early research suggests these medications may influence brain regions tied to reward and impulse control. As Dr. Elliott Lewis, a psychiatrist and board-certified obesity medicine specialist, puts it: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’

This isn’t scope creep. It’s integrated care.

Is It Safe? The Mental Health Concerns Around GLP-1s

The elephant in the room: reports of suicidal ideation on Ozempic made headlines in 2023. Should psychiatrists worry?

The evidence is reassuring. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. The FDA and EMA reviewed thousands of patient records and found no causal link between GLP-1s and suicidal behavior. In fact, many trials showed slightly lower rates of depressive symptoms in GLP-1-treated groups compared to controls.

From a safety standpoint, GLP-1s are low-risk for psychiatric destabilization. The bigger question is competence: Do you have the training to manage these medications responsibly?

Building Competency: Obesity Medicine Certification for Psychiatrists

Here’s what sets this apart from ‘side hustle prescribing’: legitimacy through training.

Psychiatrists are eligible for the American Board of Obesity Medicine (ABOM) certification. This requires ~60 hours of obesity-focused CME covering metabolic physiology, nutritional interventions, anti-obesity pharmacotherapy, and behavioral modification—then passing a comprehensive exam.

Why bother? Because it answers the scope question directly. When you’re board-certified in obesity medicine, no one can claim you’re practicing outside your expertise. You’ve demonstrated formal proficiency in treating obesity alongside mental health.

Even without full certification, completing obesity-focused CME (available through organizations like the Obesity Medicine Association) strengthens your clinical foundation and gives you confidence to manage GLP-1s safely.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Scope of Practice: Who Can Prescribe What, and Where?

Psychiatrists (MD/DO): Full Authority, But State Rules Still Apply

As a licensed physician, you have broad prescriptive authority in all 50 states. You can prescribe FDA-approved weight-loss medications (Wegovy, Saxenda, Contrave, phentermine, etc.) and GLP-1 agonists without additional licensure.

But state medical boards set standards of care. Some states—like Florida, New Jersey, and Virginia—have explicit rules about how you prescribe for obesity:

• BMI thresholds: Most require BMI ≥30 (or ≥27 with comorbidities) before prescribing anti-obesity medications.
• Informed consent: Written acknowledgment of risks/benefits.
• Follow-up requirements: Florida mandates face-to-face visits every 3 months for patients on obesity medications. Virginia requires follow-up within 30 days of starting treatment, then monthly initially.
• Comprehensive evaluation: New Jersey requires a full workup including assessment for underlying psychiatric conditions, nutritional counseling referrals, and a documented diet/exercise plan.

In telehealth, this means you must schedule regular video visits, order labs, and ensure you’re meeting your state’s standard of care—even if you never see the patient in person.

PMHNPs: It Depends on Your State (and Your Training)

Nurse practitioners face a patchwork of regulations. Roughly 24 states grant full practice authority (FPA) to experienced NPs, meaning you can prescribe independently. The rest require physician collaboration or supervision.

Full Practice Authority States (Examples):

• New York: After 3,600 hours of practice, NPs can work independently without a collaborating physician.
• Illinois: NPs with ≥4,000 hours experience and ≥250 hours CE can obtain FPA and prescribe controlled substances independently (with some Schedule II caveats).
• California: AB 890 phases in NP independence—qualified ‘104’ NPs can open independent practices starting January 2026, but California’s Corporate Practice of Medicine doctrine still requires physician involvement in clinic ownership.

Restricted/Collaborative States (Examples):

• Texas: All NPs must have a written Prescriptive Authority Agreement (PAA) with a Texas-licensed physician. The physician must oversee prescribing, conduct monthly chart reviews, and meet face-to-face with the NP monthly.
• Florida: PMHNPs cannot prescribe controlled substances independently. You need a supervising physician protocol even if you qualify for Florida’s limited ‘Autonomous APRN’ status (which excludes psych NPs anyway).
• Pennsylvania: CRNPs need a collaboration agreement with a physician. Prescription blanks must include both the NP’s name and the collaborating physician’s name.

The Practical Reality: Even in FPA states, some insurers and pharmacies demand physician oversight for high-cost drugs like GLP-1s. A Washington or Illinois PMHNP may have legal authority to prescribe Wegovy independently, but the pharmacy benefit manager might require a physician’s name on the prior authorization. This isn’t a legal requirement—it’s a business barrier—but it’s real.

Solution: Many telehealth platforms build physician medical directors into their model regardless of state NP autonomy, ensuring smooth insurance credentialing and oversight for controlled substances.

Specialty Scope: Should Psych NPs Prescribe Weight-Loss Meds?

Here’s the question NPs wrestle with: ‘I’m trained in mental health—is prescribing for obesity outside my scope?’

It depends.

If you’re managing a patient’s antipsychotic-induced weight gain, prescribing metformin or a GLP-1 to mitigate metabolic side effects is absolutely within your scope. That’s treating the whole patient.

If you’re launching a standalone weight-loss clinic for the general public with no psychiatric component, you’re on shakier ground. State boards expect nurse practitioners to practice within their population focus and training.

The smart approach? Integrate weight management into your existing psychiatric practice. Treat patients who have both mental health and metabolic concerns. Pursue additional obesity training (CME, certifications). Work with a collaborating physician who has obesity medicine experience.

This positions you as a provider offering holistic care—not someone stretching into a specialty you’re unqualified for.

Telehealth Prescribing: Federal Waivers, State Traps, and Controlled Substances

The Federal-State Divide You Need to Understand

Federally, the DEA extended COVID-era telehealth flexibilities through December 31, 2025, allowing providers to prescribe controlled substances via telemedicine without an initial in-person exam. That includes phentermine (Schedule IV), the most commonly prescribed weight-loss medication.

Sounds great, right?

Here’s the trap: State law can override federal rules.

The DEA explicitly states that teleprescribing is only permitted if it also complies with state law. And several states have enacted stricter requirements that effectively ban remote prescribing of controlled substances for weight loss.

States with Telehealth Controlled Substance Restrictions

Florida: Prohibits telehealth prescriptions of controlled substances except for treating psychiatric disorders, inpatient/hospice care, or emergency addiction treatment. Weight loss is not an exception. This means you cannot prescribe phentermine via telehealth to a Florida patient, even though federal DEA waivers allow it.

(Good news: GLP-1s like semaglutide are not controlled substances, so they’re allowed via telehealth in Florida.)

Alabama: Requires an initial in-person exam to prescribe any controlled substance. Purely remote prescribing of phentermine is prohibited.

South Carolina, Idaho: Have strict telemedicine standards that generally require in-person evaluations for controlled substance initiation.

Approximately 8 states maintain telehealth prescribing restrictions comparable to or stricter than the pre-COVID Ryan Haight Act requirements.

What This Means for Your Practice

If you’re on a telehealth platform serving multiple states, you need to:

1. Know which states prohibit remote controlled substance prescribing. Don’t assume federal waivers mean you’re cleared everywhere.
2. Geofence services where necessary. Many platforms simply don’t offer phentermine prescriptions in Florida, Alabama, etc.
3. Focus on non-controlled options. GLP-1s (semaglutide, tirzepatide) are not controlled and can be prescribed via telehealth in all states, as long as you meet standard-of-care requirements.
4. Check your state’s PDMP. Almost every state requires checking the Prescription Drug Monitoring Program before prescribing controlled substances. In Florida, it’s E-FORCSE. In Texas, it’s mandatory for opioids/benzos/barbiturates, and best practice for phentermine.

Establishing a Valid Patient Relationship via Telehealth

Most states recognize that a live video visit can establish a doctor-patient relationship equivalent to an in-person exam, provided you conduct an appropriate evaluation.

For weight management, ‘appropriate evaluation’ means:

• Documenting height, weight, BMI (patient self-reports or recent measurements)
• Reviewing medical history (prior weight loss attempts, comorbidities like diabetes or hypertension)
• Visual assessment via video (to the extent possible)
• Ordering labs if indicated (TSH, glucose, lipid panel to rule out secondary causes of obesity)
• Discussing risks, benefits, and lifestyle modifications
• Obtaining informed consent

Avoid asynchronous-only prescribing. A Mississippi physician had his license suspended in 2023 for prescribing Ozempic through an instant-messaging platform with no audio/video. The board deemed it a failure to establish a proper patient relationship.

Best practice: Initial consultation via live video, with documented follow-ups at intervals your state requires (every 3 months in Florida, every 30 days initially in Virginia, etc.).

State-Specific Compliance: What You Must Know

Florida: The Most Regulated State for Weight Loss

Florida takes obesity prescribing seriously. Here’s what you must do:

• BMI ≥30 or ≥25 with comorbidity documented before prescribing (Fla. Admin. Code R. 64B15-14.004).
• Comprehensive physical examination (can be delegated to an APRN/PA under physician supervision).
• Written informed consent from the patient.
• Provide the state-mandated ‘Weight-Loss Consumer Bill of Rights’ brochure.
• Follow-up visits every 3 months minimum to continue prescribing.
• PDMP check (E-FORCSE) before each controlled substance prescription.

Telehealth caveat: You cannot prescribe controlled substances (phentermine) via telehealth in Florida unless the patient has a psychiatric diagnosis that qualifies under the telehealth exemption—and even then, it’s risky without clear guidance.

NP/APRN rules: All Florida APRNs need a physician protocol to prescribe. Even ‘Autonomous APRNs’ (limited to certain primary care specialties) cannot prescribe controlled substances independently.

Clinic licensing: Any entity offering weight-loss treatments must register under Florida’s Health Care Clinic Act and designate a Florida-licensed MD/DO as medical director.

Texas: Strict Delegation, Strong Physician Oversight

Texas is not a full-practice state for NPs. Here’s what’s required:

• Prescriptive Authority Agreement (PAA) with a Texas physician for all NP/PA prescribing.
• PAA must detail scope of prescribing, communication protocols, chart review schedules, and monthly face-to-face meetings between NP and physician.
• One physician may supervise up to 7 APRNs/PAs (outside hospitals).
• PMP check required for controlled substances.
• Corporate Practice of Medicine doctrine: Medical decisions must remain under physician control. Non-physician-owned clinics use MSO structures.

Telehealth: Texas allows telemedicine prescribing if you establish a proper patient relationship and document the encounter. No state prohibition on controlled substances via telehealth (federal rules apply).

California: Phased NP Independence, But CPOM Still Rules

California is transitioning to NP full practice authority under AB 890:

• NPs with 3 years/4,600 hours supervised practice can apply for independent practice.
• Full independent practice (including clinic ownership) begins January 1, 2026 for certified ‘104’ NPs.
• BUT: California’s Corporate Practice of Medicine doctrine means only physicians can own medical practices. Even independent NPs must operate within physician-owned entities or professional corporations.

Prescribing: NPs cannot independently prescribe controlled substances for weight loss until they attain independent furnishing privileges. Psychiatrists have no such restriction.

Telehealth: California has strong telehealth parity laws—private insurers must reimburse telehealth equal to in-person.

New York: Reduced Practice with Post-Experience Independence

• NPs need a collaborative agreement initially. After 3,600 hours (≈2 years), NPs can practice independently without a written MD agreement.
• I-STOP law requires checking the state Prescription Monitoring Program before prescribing Schedule II-IV controlled substances (including phentermine).
• No state-specific obesity prescribing rules beyond standard of care.
• Telehealth parity mandated by state law—insurers must pay telehealth visits equal to in-person.

Illinois: Full Practice Authority After Experience

• NPs with ≥4,000 hours experience and ≥250 hours CE can obtain FPA and prescribe independently.
• Illinois Medicaid reimburses APRNs at 100% of physician rates—a major financial incentive.
• Controlled substance prescribing: FPA-NPs can prescribe Schedule III-V independently; Schedule II requires 45 hours pharmacology training and a physician consultation relationship for the first year.
• Telehealth Alignment Act ensures coverage and payment parity.

Pennsylvania: Collaboration Required, Physician Name on Scripts

• All CRNPs must have a collaboration agreement with a physician.
• Prescription blanks must include the collaborating physician’s name in addition to the NP’s.
• One physician can collaborate with up to 4 NPs.
• No FPA legislation passed as of 2025—NPs cannot prescribe independently.

Reimbursement: How You’ll Get Paid

Insurance Coverage for GLP-1 Weight-Loss Medications

A few years ago, insurance coverage for weight-loss drugs was rare. That’s changing fast.

Private Insurance:

• Many commercial plans now cover FDA-approved GLP-1s (Wegovy, Saxenda) with prior authorization.
• PA requirements typically include: BMI ≥30 (or ≥27 with comorbidity), documentation of lifestyle modifications, and attestation that the medication is part of a comprehensive weight management plan.
• Some insurers impose quantity limits—e.g., Blue Cross Blue Shield TX introduced a 30-day supply limit for new GLP-1 prescriptions to monitor adherence before approving refills.

Medicare & Medicaid:

• Historically, Medicare Part D excluded weight-loss drugs.
• Game-changer: In November 2025, the federal government announced that Medicare will begin covering anti-obesity medications like Wegovy and Mounjaro starting in 2026.
• State Medicaid programs vary—some already cover at least one GLP-1 for obesity; others are expected to expand coverage following Medicare’s lead.

This shift is massive. It opens weight-loss treatment to millions of seniors and low-income patients, creating significant demand for qualified prescribers.

Billing for Weight Management Visits

E/M Codes:

• Use standard evaluation and management codes (99202-99215 series) for outpatient visits.
• A psychiatrist managing weight alongside psychiatric care can document both problems—total complexity determines the E/M level.

Obesity Counseling Codes:

• Medicare offers G0447 (15 minutes face-to-face behavioral counseling for obesity, BMI ≥30).
• Psychiatric providers can use time-based E/M coding if most of the visit is counseling on weight management.

Telehealth Modifiers:

• Add modifier 95 or GT (depending on payer) to indicate telehealth delivery.
• Many states mandate telehealth payment parity—insurers must reimburse telehealth visits at the same rate as in-person.

Psychiatrists vs. NPs: Reimbursement Rates

• Psychiatrists (MD/DO): Reimbursed at 100% of physician fee schedule by Medicare and most insurers.
• PMHNPs: Medicare reimburses NP services at 85% of physician fee schedule. Some private insurers pay 85-100%.
• Exception: Illinois Medicaid reimburses APRNs at 100% of physician rates for all services.

Example: A routine 15-minute med check (99213 or 99214) might pay $75-$120 for a psychiatrist, $65-$100 for an NP (varies by region and payer).

For high-volume telehealth practices, even an 85% reimbursement rate can be financially sustainable—especially if you’re seeing more patients per day via telehealth than you could in-person.

The Klarity Health Advantage: Let Someone Else Handle Patient Acquisition

Here’s the reality of building a weight-loss practice:

DIY Marketing is expensive and uncertain.

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow. Most solo providers don’t have the expertise or patience.
• Google Ads for mental health and weight loss keywords cost $15-40+ per click. Realistic cost per booked patient through PPC? $200-400+.
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of providers on the same page. Zocdoc charges $35-100+ per booking, plus subscription fees.

When you factor in agency/consultant fees, ad spend testing, staff time to handle and qualify leads, no-show rates from cold leads, and failed campaigns, acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+.

Klarity Health uses a pay-per-appointment model.

Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee only when a pre-qualified patient books with you.

That means:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure—no separate platform costs
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

That’s guaranteed ROI vs. gambling on marketing channels.

For most providers—especially those starting out or scaling—a platform that handles patient acquisition removes the risk entirely.

FAQs

Can psychiatrists legally prescribe GLP-1s for weight loss?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all 50 states. As long as you meet your state’s standard of care (documenting BMI, obtaining informed consent, scheduling follow-ups), you can prescribe FDA-approved weight-loss medications including GLP-1s. Pursuing additional training in obesity medicine strengthens your clinical competence and addresses any scope concerns.

Do PMHNPs need physician oversight to prescribe weight-loss medications?

It depends on your state. Approximately 24 states grant full practice authority to experienced NPs, allowing independent prescribing. The rest require physician collaboration or supervision. Even in FPA states, some insurers and pharmacies may require physician involvement for high-cost drugs like GLP-1s. Check your state’s nurse practice act and consider working with a collaborating physician for regulatory and practical reasons.

Can I prescribe phentermine via telehealth?

Federally, yes—DEA waivers extend through December 31, 2025. But state law can prohibit it. Florida, Alabama, and several other states ban telehealth prescribing of controlled substances for weight loss. GLP-1s (semaglutide, tirzepatide) are not controlled and can be prescribed via telehealth in all states, provided you meet standard-of-care requirements.

What are the follow-up requirements for patients on weight-loss medications?

This varies by state. Florida requires face-to-face visits every 3 months. Virginia mandates follow-up within 30 days of starting treatment, then monthly initially. New Jersey requires regular monitoring but doesn’t specify exact intervals. Best practice: schedule at least quarterly video visits to monitor weight, vital signs, side effects, and adjust dosage.

Do I need special certification to prescribe GLP-1s?

No special license is required, but additional training is strongly recommended. Psychiatrists are eligible for American Board of Obesity Medicine (ABOM) certification, which requires ~60 hours of obesity-focused CME and passing a comprehensive exam. This demonstrates formal competency and addresses scope-of-practice concerns. Even without full certification, completing obesity medicine CME strengthens your clinical foundation.

Will insurance cover GLP-1s for my patients?

Increasingly, yes. Many private insurers now cover FDA-approved GLP-1s (Wegovy, Saxenda) with prior authorization. Medicare will begin covering anti-obesity medications starting in 2026. State Medicaid coverage varies. Be prepared to document BMI, comorbidities, previous weight loss attempts, and that the medication is part of a comprehensive weight management plan to meet PA requirements.

What’s the difference between prescribing for obesity vs. medication-induced weight gain?

Clinically, both may warrant a GLP-1. From a scope perspective, treating medication-induced weight gain in your psychiatric patients is clearly within your purview—you’re managing a side effect of your own prescribing. If you’re treating obesity in otherwise healthy patients with no psychiatric involvement, you’re on shakier ground unless you have obesity medicine training. The smart approach: integrate weight management into your existing psychiatric practice.

Can NPs in restricted states prescribe weight-loss meds under physician supervision?

Yes, as long as the Prescriptive Authority Agreement or collaborative agreement explicitly authorizes it. In Texas, the PAA should list weight management drugs (Schedule IV anorectics, GLP-1s) in the scope of prescribing. In Florida, the physician protocol must delegate obesity treatment. The supervising physician should have experience in obesity medicine or weight management to provide appropriate oversight.

Next Steps: Join Klarity Health’s Provider Network

If you’re a psychiatrist or PMHNP looking to expand your practice into weight management—or you’re already prescribing GLP-1s and want access to a steady stream of qualified patients—Klarity Health’s telehealth platform offers a smarter path than building solo.

What you get:

• Pre-qualified patients matched to your specialty and availability
• Built-in telehealth infrastructure (no separate EHR or platform costs)
• Both insurance and cash-pay patient flow
• Pay-per-appointment model—you only pay when you see patients
• No upfront marketing spend or monthly subscription fees

What you need:

• Active psychiatric prescriber license (MD/DO or PMHNP with prescriptive authority)
• DEA registration (if prescribing controlled substances)
• Willingness to pursue or complete obesity medicine training (recommended)
• Compliance with your state’s telehealth and weight-loss prescribing regulations

Ready to explore? Visit [Klarity Health’s provider page] to learn more about joining the network, or schedule a call with our provider relations team to discuss how the platform works and what support is available.

Weight management is no longer a niche service. It’s becoming core to comprehensive psychiatric care—and the providers who adapt early will be the ones capturing patient demand as insurance coverage expands and telehealth becomes the norm.

References

1. MedicalDirector Co. ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? 2025 Definitive Guide.’ 2025. https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co. ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025).’ Updated 2025. https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. MedicalDirector Co. ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025).’ Updated 2025. https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

4. Florida Administrative Code, Rule 64B15-14.004 – Standards for Prescription of Obesity Drugs. Effective August 8, 2022. https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

5. Foley & Lardner LLP. ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ Mondaq, July 24, 2023. https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting